
Annovis Bio (ANVS) Stock Forecast & Price Target
Annovis Bio (ANVS) Analyst Ratings
Bulls say
Annovis Bio Inc. has positioned itself advantageously in the clinical-stage pharmaceutical sector, focusing on innovative treatments for neurodegenerative diseases, with significant pipeline products including Buntanetap, ANVS405, and ANVS301. The company's progression in clinical trials, including promising interim results for Buntanetap that could modify disease progression and the strategic alignment with the FDA for potential New Drug Applications, reflects a strong commitment to advancing its lead product towards regulatory approval. Positive findings from trials and a clear roadmap for future developments enhance the company's growth potential and may lead to increased market opportunities in the treatment of Alzheimer's and Parkinson's diseases.
Bears say
Annovis Bio Inc faces significant financing risks due to a modest cash runway, which could lead to dilutive capital-raising activities. The company's pipeline is concentrated on challenging neurodegenerative diseases like Alzheimer's and Parkinson's, raising concerns over potential trial failures due to efficacy and safety issues. Additionally, there are risks associated with the lack of FDA approval for their drug filings and the possibility of unsuccessful market launches impacted by intense competition and pricing pressures.
This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.
Annovis Bio (ANVS) Analyst Forecast & Price Prediction
Start investing in Annovis Bio (ANVS)
Order type
Buy in
Order amount
Est. shares
0 shares